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Introduction 
 
 INTRODUCTION 
 
 
Discovery of antibiotics to treat infections caused by bacteria has been 
one of the most important developments of modern medicine. However, 
widespread antibiotic usage has led to the rise of drug resistance among 
bacteria. Now, antibiotic resistance is a serious global problem, resulting in 
increased health care costs, morbidity and mortality. 
(1) 
 
Mechanism of bacterial resistance to antimicrobial agents is complex 
and dynamic; the important ones being, production of ß – lactamases, AmpC 
Class ß – lactamases and Metallo- ß – lactamases. 
 
AmpC class ß – lactamases are cephalosporinases that are poorly 
inhibited by clavulanic acid. They can be differentiated from other extended 
spectrum ß – lactamases (ESBLs) by their ability to hydrolyse cephamycins 
like cefoxitin as well as other extended – spectrum cephalosporins. (1) 
Organisms producing plasmid mediated Amp-C ß – lactamases were first 
reported in the 1980’s. The genes are encoded on large plasmids containing 
additional resistance genes leaving few therapeutic options.
(1)
 Amp- C ß – 
lactam resistance (AmpC-R) in Enterobacteriaceae, their spread among other 
members and treatment failure with broad spectrum cephalosporins have been 
documented. 
(2)
 Detecting Amp C isolates is clinically important, not only 
because of their broader cephalosporin resistance, but also because carbapenem 
resistance can arise in such strains by further mutations, resulting in reduced 
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 porin expression. 
(3,4)
 However, most clinical laboratories and physicians 
remain unaware of their clinical importance. 
 
Current detection methods of AmpC – R is challenging and technically 
demanding on a routine basis. There are no CLSI guidelines for its detection. 
Multiplex PCR for AmpC-R detection is available as a research tool, but is 
expensive and is not yet available for routine use. As a result, organisms 
producing these types of ß – lactamases often go undetected and therefore have 
been responsible for several nosocomial outbreaks 
(5) 
 
We wished to address this issue by evaluating various phenotypic 
methods to detect AmpC ß – lactamases and compare against the genotypic 
methods . 
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Aim and Objectives 
 
 AIM AND OBJECTIVES 
 
 
AIM: 
 
 
To evaluate the presence clinical 
isolates of Enterobacteriaceae Amp C 
production of these strains. 
 
 
 
 
 
 
of Amp C beta- lactamase among and 
to detect the genetic basis for 
 
OBJECTIVES: 
 
 
 To screen for Amp C β – lactamase producing clinical isolates of 
Enterobacteriaceae.

 To compare different AmpC phenotypic detection methods.

 To  detect  the  presence  of  Amp C   genes  among  these  clinical
 
isolates and compare  against the phenotypic  methods. 
 
 To know the antibiotic sensitivity pattern of these clinical isolates.
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Review of Literature 
 
 REVIEW OF LITERATURE 
 
 
HISTORY OF AmpC BETA-LACTAMASES 
 
 
 
 
The frequency of Gram negative bacterial infections producing disease 
has varied widely over the past century. Before the use of antibiotic drugs, 
Gram negative infections were uncommon in the 1920 and 1930’s. (6) In the 
1960’s to 1980’s, percentage of infections caused by Gram negative pathogens 
increased. Prior exposure to antibiotic drugs was, and remains today, a 
principal risk for developing Gram negative infections . 
 
 
 
In later years, Gram positive pathogens became more prominent. 
because of   introduction  of 3rd generation in  1985.  Since,  1990’s  gram 
negative  pathogen  became prominent. Gram positive  pathogens are treated 
with penicillin’s,  1
st
,  2
nd
, 3rd generation of   cephalosporins of beta- 
lactamase,      
 
 
 
 
Beta-lactamases are heterogenous bacterial enzymes that cleave the 
beta-lactam ring of penicillins and cephalosporins to inactivate the antibiotic. 
(7)
 ESBL are enzymes that mediate resistance to 4
th
 generation cephalosporins 
and monobactam, but, do not affect cefamycins, or carbapenems. They are 
inhibited by beta-lactamase inhibitor combinations such as clavulanic acid, 
sulbactam & tazobactam. Therefore, organisms 
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 resistant to 3
rd
 generation cephalosporins but sensitive to beta-lactam- beta-
lactam inhibitor combination are likely to contain ESBL. 
(8)
 they; also named, 
as penicillinase, are enzymes produced by bacteria that provide multiresistance 
to beta- lactam antibiotics as penicillin, cephalosporin, cephamycin, 
carbapenems., they are relatively resistant to beta-lactamase. 
 
 
 
These drugs have a common compound in the molecular structure, a 
four - atom ring called as Beta-lactam. (8) The lactamase enzyme breaks the 
beta-lactam ring open, deactivating the molecules of antibacterial 
 
properties. These are encoded by chromosomal genes, and by transferable 
genes on plasmids, and transposons. 
 
 
 
They frequently reside on integrons which often carry multiple 
resistance determinants. Among Gram negative organisms, the rise in 
ampicillin resistance is due to the TEM-1 a plasmid encoded beta-lactamase 
named after a Greek patient Temoniera, in whom the first isolate was 
recovered. 
(9)
 These antibiotics are mostly used to treat a broad spectrum of 
Gram positive and Gram negative bacteria. 
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 PENICILLINASE: 
 
 
 
 
Penicillinase is a particular type of beta-lactamase, appearing to have 
specificity for penicillins, hydrolyzing the beta-lactam ring. Weight of 
penicillinases tend to cluster near 50 kD. Penicillinase was the first beta-
lactamase to be identified. It was first isolated by Abraham and Chain in 1940 
from Gram negative E.coli . Beta-lactam antibiotics are a broad class of 
antibiotics, that contain a beta lactam ring in their molecular structure. It 
includes penicillin derivatives, cephalosporins, monobactams and 
carbapenams. 
 
 
 
AmpC CLASS BETA-LACTAMASES: 
 
 
 
 
Among the beta-lactamases, the most common is production of 
ESBLs & AmpCs. Ambler class C and Bush group 1 beta-lactamase enzyme, 
AmpC Beta-Lactamases are being reported worldwide. These enzymes confer 
 
resistance to penicillin, 1
st
, 2
nd
 and 3
rd
 gen cephalosporins cephamycin,and 
monobactams. These are poorly inhibited by clavulanic acid , sulbactam etc. 
but are inhibited by cloxacillin, and phenyl boronic acid. These are 
cephalosporinases which are not inhibited by Clavulanic acid, tazobactam & 
 
sulbactam. Amp C Beta-lactamase production is frequently associated with 
production of multi drug resistance. (10) Gram negative bacilli resistant to 
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 beta- lactams are increasingly being isolated from ill and hospitalized 
 
patients. 
 
 
 
 
Selected AmpC Beta lactamases of Gram negative bacteria: 
 
 
 
 
ACC-1, ACT-1, CEF-1, CMY FAMILY, DHA-1, DHA-2, FOX FAMILY, 
LAT FAMILY, MIR-1, MOX-1 AND MOX-2. 
(11) 
 
 
 
Amp C Gene: 
 
 
 
 
Transmissible plasmids have acquired genes for Amp C enzymes, which 
consequently can now appear in bacteria lacking or poorly expressing a 
chromosomal bla Amp C gene such as E.coli, Klebsiella, and Proteus 
mirabilis. 
 
 
 
Amp C INFECTION: 
 
 
 
 
Carbapenems  can  usually  be used  to  treat  infection due  to  Amp 
 
C producing bacteria, but, carbapenem resistance can arise in some 
organisms by mutation that reduces influx- outer membrane porin loss / 
enhanced efflux or efflux pump activation. 
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 The  first  bacterial  enzyme reported  to  destroy  penicillin  was  the 
 
Amp C beta-lactamase of E.coli. In 1965, Swedish investigators started a 
 
study of genetics of penicillin resistance in E.coli. (12) Mutations with 
 
stepwise increased resistance were termed ampA & ampB. 
 
 
 
 
Amp A strains overproduced beta lactamase, was regulatory role for the 
ampA gene. Amp B gene were found to have an altered cell envelope, AmpC 
was the structural gene for the enzyme In 1981, ampC gene from E. coli was 
reported, it differed from TEM-1 penicillinase. 
 
 
Amp C enzyme has molecular wt of 40,000 and pH was alkaline. 
(13)
 It 
has hydrolytic activity, and rapid action in 1
st
 gen of cephalosporins, slow 
 
but kinetically effective in 2nd & 3rd gen , slow kinetically ineffective in 4th gen. 
and poorly inhibited by Sulphones, but, Carbapenams are nearly stable & not 
inhibited by Clavulanate. 
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Fig -1 Molecular structure of AmpC beta lactamases from E coli 
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 CLASSIFICATION. 
 
 
 
 
Beta-Lactamases Can be classified according to their aminoacid 
structure in to four molecular classes A through D as first suggested by 
Ambler. 
(14)
 The Bush- Jacoby- Medeiros system classifies the enzymes 
according to their substrate profile and susceptibility to beta- lactamase 
inhibitors such as clavulanic acid in to several functional groups. 
(3) 
 
 
Class A, C & D-Hydrolyse the β-lactam ring through a serine residue at their 
active site. 
 
 
Class B- use Zinc to  break the  amide  bond. 
 
 
 
 
CLASS C Amp C- type beta-lactamases. 
 
 
 
 
Class C type 
cephalosporins, 
 
 
 
beta-lactamases 
 
Broad spectrum 
 
 
 
 
that  hydrolysed   cephems,  cephamycins, 
penicillins, monobactams beta-lactamase 
 
inhibitors. 
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 Table – 1 Classification of Betalactamases 
 
 
Functiona 
Major 
Molecular 
  Inhibition 
sub Functional group 
 
by 
l group class 
 
group 
  
clavulanate     
      
1  C Cephalosporinases  often  -- 
   chromosomal enzymes  in GNB,  
   but, may be plasmid encoded,   
   confer resistance to  all classes of  
   β-lactams,   
      
2 2a A Penicillinases, confer resistance to + 
   all penicillins, primarily from   
   Staphylococcus, Enterococci.   
      
 2b A Broad spectrum β-lactamases  + 
   primarily from GNB.   
      
 2be A ESBLs confer resistances to  + 
   Oxyimino-cephalosporines&   
   monobactams   
      
 2br A Inhibitor resistance TEM β-  -   (+) for 
   lactamases  tazobactam 
     
 2c A Carbenicillin hydrolyzing enzymes + 
     
2 2d D Cloxacillin hydrolyzing enzymes +/_ 
     
 2e A Cephalosporinases confer resistance + 
   to monobactam   
     
 2f A Carbapenem-hydrolysing enzymes + 
   with active site serine.   
      
3 3a,3b,3c B Metallo β lactam classes,except  _ 
   monobactams.   
     
4   Miscellaneous unsequenced enzymes _ 
   that do not fit into other groups   
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 Types of  AmpC beta-lactamases. 
 
 
Chromosomal- &  plasmid  mediated. 
 
 
 
SPICE. ORGANISMS. : 
 
 
 
 Colloquial   acronyms for Gram  negative bacteria that have 
inducible, chromosomal, β – lactamase  genes known  as  AmpC .Resistance 
may  not be  detectable initially,  but,  appears  after  a  period  of  exposure 
to  β – lactam antibiotics. Organisms in these  groups include, Serratia spp, 
Pseudomonas, indole positive Proteae,   Providencia, Morganella 
morganii,Citrobacterspp, Enterobacter spp. 
(15)
 These organisms are more 
virulent than susceptible gram negative  bacteria.    
 
 
 
 
Plasmid-mediated; transmissible.. Mostly detected organisms 
without intrinsic amp c gene are Ecoli ,Klebsiella ,Proteus mirabilis & 
Salmonella spp., 
 
 
Amp C Beta- lactamases are typically encoded on the chromosome 
of many gram –ve bacteria including Citrobacter, Serratia, and Enterobacter 
spp where its expression is usually inducible. AmpC type beta-lactamases may 
also be carried on plasmids. 
(16) 
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 Amp C beta-lactamases, in contrast to ESBLs, hydrolyse broad and 
extended spectrum cephalosporins, but are not inhibited by beta-lactamase 
inhibitors such as clavulanic acid 
 
 
Differentiating ESBL & beta-lactamases. 
 
 
 
 
ESBL& AmpC β-lactamases are in a variant of de-repressed state, 
cause hydrolysis of β-lactams, it can be difficult to identify the cause of 
resistance. But,both these are share the hydrolytic activity to the penicillins and 
the 1
st
,3
rd
 generation of cephalosporins. And they are inherently resistance to 
the inhibitors. such as Amoxy-clavulanate, Ampicillin- sulbactam, and in some 
cases of Piperacillin-Tazobactam. 
(17)
 Conversely, ESBL- producing 
organisms may or may not be resistance to these same agents. AmpC 
producing organisms are susceptible to ATM, where ESBL are fundamentally 
resistance to ATM. 
 
 
Even in a wild type strain, Ampc β lactamases will hydrolyse against 
the cephamycins ,but ESBLs are susceptible to cephamycins. Fourth generation 
cephalosporins are very stable opposite to AmpC beta-lactamases, and 
relatively stable against ESBLs. 
 
 
Different type of resistances are played. One of the resistance type is 
Acquired resistance to cephalosporins is due to 
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 1. Affinity of antibiotics was reduced due to altered target proteins of PBS 
 
 
 
 
 
2. Impermiability of antibiotic, so it does not reach the active site of action 
 
 
 
 
 
3. Elaboration  of  beta-lactamases which destroy cephalosporinases. 
 
 
 
AmpC Beta Lactamases can be differentiated by their ability to 
hydrolyse cephamycins like cefoxitin as well as other ESBL. 
(18) 
 
 
Organism producing plasmid mediated AmpC Beta- lactamases were 
first reported in 1980’s, after the introduction of 3rd generation cephalosporins 
they acquire Amp C beta-lactamases on plasmids and hyper produce 
chromosomal AmpC , which is normally produce at lower level 
 
 
Genes for AmpC also found on plasmids that transfer non 
 
inducible cephalosporin resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 Amp C β-Lactamase resistance. 
 
 
 
AmpC producing organisms causes  reistance to penicillins & 
cephalosporins through  hydrolyasis and  opening  of  the  beta-lactam  ring, 
it  will   also producing inherently resistant   to the activity   of 
cephamycins.      
 
 
 
Genes  encoding  for  AmpC β-lactamases   are plasmid mediated or 
chromosomally mediated. 
(19)
 In general  chromosomal AmpC will  undergo 
hyperproduction in   the   suitable   environment.   Some   gram   negative 
organisms of ‘SPACE’ ORGANISMS are in a state of    chromosomally 
mediated Amp C hyperproductive  state.  Here,   
 
 
 
 
Ampicillin, Amoxycillin, and Cefazolin are regarded as strong inducers, 
excellent substrate of Amp C β-lactamases.Beta-lactamase inhibitors are also 
inducers of AmpC and can gives to treatment failure with drugs appeared 
susceptible. AmpC β-lactamase commonly with in the 
 
periplasm porin entry of these agents is the rate limiting step in hydrolysis by 
AmpC β –lactamases, due to the zwitterionic structure , does not require porin 
for entry to the periplasmic space can overcome the inactivation rate. 
(20)
 
AmpC genes located on plasmids are constitutively produced, where as 
chromosomally mediated Amp C acting in a hyper production state. Baseline 
state represses AmpC production. 
 
 
15 
 The antimicrobials that hydrolyse bacterial cell wall, a series of 
 
1,6,anhydro-N-acetylmuramic acid  peptides  are  produced  and  they  buildup 
 
they compete with  uridine di phosphate- N –acetylmuramic acid peptides 
for binding  with Amp R, a transcriptional   regulatory  enzyme thyat  at  a 
base line  
 
 
 
 
Another regulatory protein, AmpD, It was responsible for cleavage of 
stem peptides from 1,6,anhydro-N-acetyl muramic acid which decreases their 
affinity to bind to Amp R 
 
 
Induction of AmpC transcription occurs as increased concentration of 
1,6, anhydro N acetyl muramic acid, so not able to cleave all of the stem 
peptides leads to increased Amp C transcription. So induction only explains the 
wild type resistance profile of the AmpC producing organisms. Stable de- 
repression is felt to be the reason for AmpC over expression leading to 
resistance but, susceptible in vitro. 
(21)
 This occurs secondary to Amp D 
mutation., which ultimately inhibit cleave of peptide bond. These resistance 
mechanism, identify the most clinically prudent empiric antimicrobial therapy 
difficult . 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig -2 : Regulation of AmpC in Enterobacteriaceae 
 
 
 
 
Beta lactam differ in their inducing abilities strong inducers, good 
substrates for AmpC betalactamase are ampicillin, amoxicillin, benzyl 
penicillin& Ist gen of cephalosporins. Cefoxitin, imipenam are also strong 
inducers but are much more stable for hydrolysis. 
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 Weak inducers and weak substrates but can be hydrolysed if enzymes 
are supplemented are 3 rd, 4 th gen cephalosporins, piperacillin & aztreonams. 
MIC of weakly inducing oxyimino beta lactam are increased with 
 
AmpC hyperproduction. 
(22)
 But, MIC of strong inducers shows little change 
with regulatory mutations. 
 
 
Beta lactam inhibitors are also inducers, especially clavulanate, has little 
inhibitory effect on AmpC, but can paradoxically appear to increase AmpC 
mediated resistance.this effect of clavulanate is important for P.aeruginosa. and 
this antagonize the antibacterial activity of Ticarcillin. 
(23) 
 
 
PUMPS & PORINS: 
 
 
 
  Important   determinants of the resistance spectrum is the  rate 
at which the  substrate  is  delivered  to the enzymes.  The concentration of 
β-lactam substrate in the periplasm is a  permeability function of the 
cell’s  outer  membrane,  and  through the  porin channel  β-lactam  penetrate 
and  of  efflux pump,  which  transport them  out  of the cell. Vu & Nikaido 
noted out, concentration  of β-lactam in  the  periplasm  necessary  to  inhibit 
target penicillin  binding  protein, decreasing the number of porin  entry 
channel  or  increasing  efflux  pump expression can lower influx and 
further augments enzyme deficiency.
(24)
 But,  carbapenem resistance in 
clinical isolates involves  various combination of overproduction of 
     18          
 AmpC, decreased production of porin channel for drug entry, and activation of 
other efflux systems. Zwitterionic molecules such as Cefepime,& Cefpirome 
have the advantage of penetrating the outer bacterial cell membrane rapidly 
than Cefotaxime, Ceftrioxone.
(25)
 . 
 
 
Global distribution of strains producing plasmid determined 
cephalosporinases. They have been found in 
 
 
Africa,  - Algeria, Tunisia. 
 
 
Asia; India, Japan, Pakistan, South Korea. 
 
 
Europe; France, Germany, Greece, Italy, Sweden,  UK. 
 
 
Middle east ; Saudi Arabia, 
 
 
North America; US. 
 
 
South ; central America 
 
 
Plasmid mediated AmpC β lactamase have been discovered world wide, 
according to resistance produced by 
 
 
CMY ; Cephamycin ‘ 60.00.00,000- 60 Crore 
 
 
FOX ; Cefoxitin. ; 1.55,00,000 
 
 
MOX ;  Moxalatem ; 1.04,00,000 
 
 
LAT ; Latamoxif  ; 3,00,000 
 
19 
 To the type of  β lactamase such  as AmpC type ; ACT ; 20,00,000 
 
 
ACC ; (AMBLER CLASS C) 
 
 
To the site of  discovery MIR;  ( MIRIAM  HOSPITAL IN  PROVIDENCE) 
 
 
-69,00,000 
 
 
 
DHA ; Dharan hospital in Saudi arabia. ; 1.07,00,000 
 
 
 
In Greece - Plasmid mediated LAT-2, CMY-2, have been found in 
clinical isolates of Enterobacter aerogenes simultaneously with its appearance 
in clinical strains of E.coli, & Klebsiella. In France; plasmid mediated ACC -1 
found in E.coli, Proteus spp, from urine samples. 
 
 
In UNITED STATES ; Ceftrioxone resistance Salmonella was isolated from 
symptomatic patients. 
 
 
CMY-2;  Spread from Pakistan to UK ,  India TO UK, Algeria to France. 
 
 
 
CMY-4;  From India  to  Sweden. 
 
 
 
Mox-2;p  Greece to  France. 
 
 
 
ACC; Tunisia to France, FOX - from Guatimala to Germany. 
 
 
 
Most of the plasmid mediated Amp C enzymes are isolated from 
ICU,or post operative, post organ transplant cases, malignancy with 
20 
 antimicrobials users Most Amp C producing nosocomial infections are the 
causes of outbreaks. 
 
 
PHYLOGENY: 
 
 
 
The ancient enzymes of serine beta lactamases were originated more 
than 2 billion yrs ago. AmpC enzymes are divided from a common ancestor in 
to class A & class D.AmpC enzymes from organism of same genus cluster 
together, but, AmpC beta lactamases of Pseudomonas, Enterobacteriaceae, 
Acinetobacter are distinctly related. 
(26) 
 
PLASMID –MEDIATED AmpC BETA LACTAMASES. 
 
 
 
Plasmid mediated Amp C beta-lactamase. 
 
 
 
Since, 1989 plasmid –encoded AmpC genes found around the world in 
nosocomial isolates and easily detected in Enterobacteriaceae family. Minor 
differences in amino acid sequence given rise to families, 
 
 
43 CMY alleles, 7 varietes of FOX, 4 varieties of ACC, LAT, & MIR, 3 
varieties of ACT, MOX, 2 variety of DHA. These are determined by 
chromosomal genes, and represent progenitor for the plasmid - determined 
enzymes. 
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 This plasmid enzyme- 
 
related, and 
 
very 
 
closely 
 
to chromosomally 
 
determined AmpC enzymes. (27) 
 
 
 
Ex- CMY has 6 varieties;CMY-1, 8, 9, 10,11,& 19 related to 
 
chromosomally determined AmpC enzymes in Aeromonas spp. Other enzymes 
are related to Citrobacter freundii. 
 
 
LAT-2 was identical to CMY-2, LAT-3 was identical to CMY-6, 
and LAT4 was to LAT-1 
 
 
Plasmid – mediated enzymes  confer resistance to broad spectrum of 
 
beta-lactams including penicillin, oxy imino- beta –cephalosporins, 
cephamycins, Astreonam. but, ACC-1 resistance to cephamycins, and cefoxitin 
inhibited. The genes for ACT-1,DHA-1,DHA-2,& CMY-13 are linked to ampR 
genes, and are inducible. while others are not. AmpC plasmids lack ampD 
genes, but the expression of ACT-1 increased with the loss of chromosomal 
Amp D function. 
(28) 
 
AmpD – deficient E. coli producing ACT-1 sensitive to imipenam, 
but, the same in K.pneumoniae carrying ACT-1 plasmid associated with a loss 
of outer membrane porins, they provide, resistance to carbopenams, oxy-imino- 
beta- cephalosporins. But, remain sensitive to cefepime. 
 
 
Plasmids carrying genes for AmpC beta- lactamases carry other gene 
resistance including aminoglycosides, chloramphenicol, quinolones, 
22 
 sulphonamides, tetracyclines, trimethoprims, & TEM-1, CTX-M3,SHV 
varieties. The AmpC gene is usually a part of integran and the same gene can 
be incorporated in to different backbone on different plasmids. A variety of 
genetic elements are implicated in the mobilization of AmpC genes onto 
plasmids. 
(29) 
 
The insertion sequence associated with many CMY alleles- CMY-
2,4,5,7, 12, 14 15,16,21,31,& 36, as well as ACC-1, 4. This sequence plays a 
dual role, and involved in the transposition of adjacent genes,has ability to 
mobilize a chromosomal bla gene on to a plasmid. It can supply an promoter 
for the high level expression of neighbouring gene other. Bla-AmpC genes are 
situated adjacent to an insertion sequence common region, involved in gene 
mobilization in to class1 integrons. 
(30) 
 
Genes for several CMY varieties , DHA-1, MOX-1, are so linked. But, 
the gene for CMY-13, and its ampR gene are bounded by directly repeated 
IS26 elements made up of a transposase gene with inverted terminal repeat 
segments. Other elements are involved in capturing the genes for FOX-5, MIR-
1, &MOX-2. 
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 Chromosomal AmpC Enzymes. 
 
 
 
High level AmpC beta-lactamase production by mutation, the 
development of resistance upon therapy is concern. Ex - biliary tract infection 
with malignant bile duct obstruction was identified as risk factor for resistance 
development. Combination therapy did not prevent resistance emergence.low 
level expression of AmpC beta-lactamase in E.coli, high level producers 
identified in clinical specimens,as cefoxitin - resistance isolates with stronger 
AmpC promoters or mutations that destabilize the normal AmpC attenuater. 
(31) 
 
 PCR, and sequencing  in different promoter or attenuator varients. 
In a few strains,  the  integration  of  an  insertion  element created  a new & 
stronger ampC promoter. 
(32)
  These   strains are   not only   resistant to 
cefoxitin but also  typically resistant to  ampicillin,, ticarcillin,cephalothin, 
 
and beta- lactam combination with clavulanic acid and have reduced 
susceptibility or resistant to ESBL . 
 
 
Few E. coli  strains with up promoter mutation have  some 
alteration in  bla AmpC , expanding its resistance spectrum, with  loss  of 
outer  membrane  porins  can augment the resistance  phenotype further. 
These   strain   remain   susceptible   to cefepime and   imipenem, but, may 
become ertapenem resistance upon therapy is concern. .  
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 Clinical relevance: 
 
Plasmid- mediated AmpC enzymes. 
 
 
 
Infection caused by gram – ve organisms expressing plasma 
 
mediated  AmpC beta-lactamases. But, its action  limited, because  they are 
usually  resistant  to  all  beta- lactam antibiotics. Except for cefepime, 
cefpirome, and  the  carbapenams constitutive  over  expression .  of AmpC 
beta-lactamases  in  gram –ve  organisms occur  either by  deregulation of 
the   amp C chromosomal gene or   by transferable ampC gene on a 
plasmid.the   transferable   ampC gene products are commonly called 
 
plasmid mediated AmpC beta- lactamases. 
(33)
 Mobilization from the genome 
of species carrying inducible/ de- repressed bla/ampC such as Citrobacter 
frreundii and Morganella morgagnii by plasmids in to E. coli, and K. 
pneumonia. 
 
 
The recognition of plasmid mediated AmpC beta-lactamases in 
E.coli and Klebsiella spp, the world wide distribuition AmpC resistance is 
important. So, very difficult to detect clinically, and no CLSI guideline also. 
The detection of AmpC production is challenging, since the hyperproduction of 
enzyme in association with OMP F porin loss in E.coli or porin deficiency in 
K.pneumoniae can produce phenotypic resistance. Detection of plasmid- 
mediated AmpC producing isolates is critical for epidemiological studies, 
hospital infection control. Because the gene can be spread to other organisms. 
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 Genes for Amp C β- Lactamases are found on chromosomes of 
several members of the Enterobacteriaceae family including E. coli, 
Enterobacter, shigella, providencia, Citrobacter freundii, Morganella morganii, 
Serratia marcesens, (34) 
 
 
Amp C β-LACTAMASE- associated Diseases 
 
 
 
In recent years,  various studies, have been  conducted  on  the 
occurrence of AmpC  producing   bacteria in humans.  It is  being  observed 
more  and more  AmpC Producing bacteria play a major  role in health 
care facilities as the pathogen that cause so called Nosocomial 
infection, Hospital acquired  infection,   &  risk of infection via food 
 
with the different type of pathogens , especially Salmonella, EHEC, 
Klebsiella., and also produced wound infection, urinary tract infection, 
VAP,Meningitis, septicemia, CAUTI, mortality and morbidity increased in 
immunocompromised patients, than immune competent. 
(35) 
 
 To  Enable   bacteria to  produce AmpC, they must carry the 
necessary genetic information- Resistance genes. As they  are passed 
from  one bacteria generation to the  next  during  cell  division called 
“VERTICAL  TRANSFER’,  the  propagation and distribuition of these 
bacterium also  contribute  towards the spread  of the resistance genes. 
Poor  hygiene,  in  hospitals,  animal shed, & home play a  major  role in 
the carryover of  the bacteria.          
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 Because the resistance gene vary often lie on transmissible gene 
section, they can also be e xchanged between bacteria of same type or different 
types called .HORIZONTAL GENE TRANSFER’ The big problem here is the 
harmless intestinal bacteria can pass on the genes for Amp C to pathogenic 
bacteria, such as ‘ Salmonella’ Infections are transmitted by food stock home 
handlers, pet animal handlers, health care workers. So, risk of infections 
occurred by in between animals or animals to human by pet handlers. 
(36) 
 
 
 
 
In India Amp C enzyme producers were found among Gram 
Negative bacteria in Guru Tegh Bahadur Hospital Delhi in 2003. In the same 
year Subha et al., in Chennai, Shahid et al in Aligarh and Ratna et al., in 
 
Karnataka reported Amp C  lactamase producing Enterobacteriaceae in the 
clinical isolates. 
(38) 
 
Detection of Amp C 
 
 
 
Detection of the resistance medicated by class C  Lactamases 
remains a challenging issue considering that transferable plasmid mediated 
class C –lactamases are of world wide concern. Several  methods that use 
 
the Kirby- Bauer disk potentiation method  with some  Lactamases inhibitors 
 
or the  three dimensional methods  have been developed and a cefoxitin agar 
medium  based  assay that uses preparations  of bacterial cell extracts  also 
developed. However  these methods  are technically intricate and interpretation 
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 of their results in not sufficiently simple for routine use in clinical 
microbiology laboratories. PCR or multiplex PCR analysis are able to provide 
 
satisfactory results in the identification and classification of genes for  
Lactamases, but equipment availability is limited to medical institutions such 
as university hospital. They are costly and require time consuming techniques. 
An enzyme-linked immunosorbent assay has also been developed and has 
 
known sensitivity and specificity for the detection of certain class C  - 
Lactamases. This technique is less costly than genetic methods, but it is not 
sensitive for the detection of class C  Lactamases that possess less than 70% 
 
homology to CMY – 2. (39) Thus practical and simple methods for detection of 
 
the resistance medicated by plasmid- mediated class C - Lactamases are 
urgently needed for enhanced infection control. 
 
There are no CLSI or other approved criteria for Amp C 
detection.organism producing Amp C beta lactamase gives positive ESBL 
screening test, but fail the confirmatory test and increased sensitivity to 
clavulanic acid so, confirmatory test are needed. 
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 Phenotypic method; 
 
 
 
 Amp C disc test

 Disc antagonism test

 Ceftazidime- imepenem disc antagonism test.
 
 Boronic acid inhibitor based  test 
 
 Cloxacillin  combined disc diffusion test

 Double disc synergy test

 Modified three dimension test
 
 
 
MOLECULAR METHOD BY MULTIPLEX PCR METHOD. 
 
 
 
 Phenotypic  test cannot distinguish various  families of  plasmid 
mediated Amp C enzymes but, also identified chromosomally determined 
Amp C enzymes  with an  ESBL. For  this, the  current  method  of  Gold 
standard for  plasmid mediated Amp C detection,  multiplex PCR  has been 
improved by utilizing Six  primer pairs,to  which a seventh pair for  CEF-1 
beta lactamase could be added. 
(40) 
Compared to  ESBL  producers, isolates 
 
producing AmpC beta-lactamase are resistant to additional betalactams and 
betalactam inhibitors and developing resistance to Carbapenems. 
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 PREVENTION AND CONTROL OF INFECTION CAUSED BY AmpC 
 
PRODUCING ORGANISMS. 
 
 
 
Amp C Producing bacteria are carried in the feces, which may spread 
via food chain, thereby producing reservoir of multiple resistant bacteria in the 
gut. It can be spread from person to person by contaminated hand, untrained 
person handling with urinary catheter in hospitalised patient, so, urinary 
infection commonly occur in patient after admission, also associated chest 
infection, wound infection causing septicemia, so, increasing prevalence of 
mortality and morbidity . 
 
 
Common principle of control measures are Hand washlng standard 
precaution and scrupulous hand hygiene are used. Area of concern, particularly 
transmission of infection occur in neonatal ward surgical ward, ophthalmic 
ward, post operative ward, & important of Burns patient care are needs 
intervension therapy 
 
 
There are different type of MDR –GNB are greate or lesser concern, 
flexibly judged by Microbiologist,& Infection prevention, control team. So, 
continuous screening, review, diagnosis are done. Drug resistant pattern are 
continuously monitored. 
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 Decontamination procedures are followed, excessive usage of 
antimicrobials are avoided or controlled by Health board team. Avoid reusable 
drugs infection surveillance is very important. 
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Materials and Methods 
 
 MATERIALS AND METHODS 
 
 
 
This study was conducted after obtaining IHEC approval at the 
Diagnostic microbiology department, PSG Hospitals. 
 
 
 
STUDY PERIOD: Jan 2016 – July 2017. 
 
 
GEOGRAPHIC AREA: PSG Hospitals, Coimbatore 
 
 
 
 
SAMPLE SIZE: 
 
 
Out of the 71067 various specimens received for culture and sensitivity 
at the microbiology department during the study period, 16552 microorganisms 
were isolated, of which 7123 (43.3%) were enterobacteriaceae identified after 
processing by standard microbiological techniques, colony morphology Gram’s 
staining, motility and biochemical reactions. (Fig-3a & 3b). 
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 Sample size determination:      
Formula  used  :  n= t 2 x p ( 1 – p) / m
2 
  
Where,        
n = required sample size.      
t= confidence level at  95% ( standard value of  1. 96 ) 
p= estimated prevalence of Amp C producers .  
m = margin of  error at 5% ( standard value of 0.05) 
Es timated  prevalence from hospital statistics ( p ) = 0. 02 
n = 1.96 x 1. 96 x 0. 2 ( 1 – 0. 2 ) / 0. 05 x 0.05   
n= 245 .8 ( 250)       
Sampling: Consecutive sampling     
 
 
Inclusion Criteria: All Gram negative clinical isolated identified 
as Enterobacteriaceae 
 
Exclusion Criteria: 
 
 
1. Gram positive Cocci / Bacilli 
 
2. Gram neagative bacilli other than Enterobacteriaceae 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
 
 
 
Fig – 3a: Culture and biochemical characteristics of E coli  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig – 3b: Culture and biochemical characteristics of  
Klebsiella pneumoniae  
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 The enterobacteriacae identified were subjected to antibiotic 
 
susceptibility testing by Kirby Bauer’s disc diffusion method. 
 
 
 
Antibiotic susceptibility testing by Kirby Bauer’s Disc Diffusion method: 
 
 
 
The Kirby-Bauer method is used for antimicrobial susceptibility testing 
which is recommended by the CLSI 2015. The accuracy and reproducibility of 
this test are dependent on maintaining a standard set of procedures as described 
here. 
 
 
At least three to five well-isolated colonies of the same morphological 
type were selected from an agar plate culture. The top of each colony was 
touched with a loop, and the growth was transferred into a tube containing 4 to 
5 ml of a suitable broth medium such as peptone water culture was incubated at 
35°C until it achieved or exceeded the turbidity of the 0.5 McFarland’s 
standard(usually 2 to 6 hours). The turbidity of the actively growing broth 
culture was adjusted with sterile saline or broth to obtain turbidity optically 
comparable to that of the 0.5 McFarland’s standard by visually comparing the 
inoculums tube and the 0.5 McFarland’s standard against a card with a white 
back ground and contrasting black lines. That resulted in a suspension 
containing approximately 1 to 2×10
8
 CFU/ml for E.coli ATCC 25922. 
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 Inoculation of Test Plates: 
 
 
 
Optimally, within 15 minutes after adjusting the turbidity of the 
inoculum suspension, a sterile cotton swab was dipped into the adjusted 
suspension. The swab was rotated several times and pressed firmly on the 
inside wall of the tube above the fluid level. This will remove excess inoculum 
from the swab. The dried surface of a Muller –Hinton agar plate was inoculated 
by streaking the swab over the entire sterile agar surface. This procedure was 
repeated by streaking two more times, rotating the plate approximately 60° 
each time to ensure an even distribution of inoculum. As a final step the rim of 
the agar was swabbed. The lid was left for 3 to 5 minutes, but not more than 15 
minutes ,to allow for any excess surface moisture to be absorbed before 
applying the antibiotic discs. 
 
 
Application of Discs to Inoculated Agar Plates: 
 
 
 
Antimicrobial discs were dispensed onto the surface of the inoculated 
agar plate and were pressed down to ensure complete contact with the agar 
surface distributed evenly so that they were no closer than 24 mm from center 
to center. The plates were inverted and placed in an incubator set to 35°C 
within 15 minutes after the discs were applied. 
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 Reading Plates and Interpreting Results: 
 
 
 
 
After 16 to 18 hours incubation, each plate was examined. If the plate 
was satisfactorily, streaked, and the inoculum was correct, the resulting zones 
of inhibition will be uniformly circular and there will be a confluent lawn of 
growth.. The diameter of the zones of complete inhibition were measured, 
including the diameter of the disc, zones were measured to the nearest whole 
millimeter, using sliding calipers or a ruler, which was held on the back of the 
inverted petriplate. ( Fig –4). 
 
 
 
 
 
Fig –4: Antibiotic susceptibility testing 
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 Cefoxitin Screening test:
42 
 
 
All the organisms speciated as Enterobacteriaceae were subjected to 
Cefoxitin screening by the standard Kirby bauer’s disc diffusion method CLSI 
2015 
43
. A 30 µg Cefoxitin disc was placed on the inoculated medium and 
incubated at 37 degree C overnight. The zones of clearing around the discs 
were measured .For all the isolates cefoxitin resistance was identified when the 
zone diameter was ≤ 18 mm ( Fig - 5) Cefoxitin resistance isolates were 
subjected to the following AmpC ß – lactamases detection methods. 
 
 
 
 
 
 
 
Fig – 5 : AmpC betalactamases screening assay using 30μg  
Cefoxitin disc  
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 About 256 non repeat randomly selected cefoxitin resistant isolates were 
tested for AmpC β lactamase production by each of the following tests. 
 
1. Modified three dimensional test ;  CONFIRMATORY  TEST. 
 
2. CIAT; Ceftazidime-Imipenem antagonism test. 
 
3. Boronic acid inhibitors based test. 
 
4. Cloxacillin- combined  disc diffusion test. 
 
5. Disc Antagonism test 
 
6. Double disc Synergy test. 
 
 
 
Modified three dimensional (M3D) AmpC assay
44
: 
 
 
 
The M3D assay was performed as described by Coudron et al and was 
used as the Gold Standard for detecting AmpC-R.It detects both inducible and 
non inducible ampc β lactamases producing isolates. Crude enzyme 
preparations was made by freezing and thawing five times the cell pellets from 
centrifuged tryptic soy broth culture. A lawn culture of E coli ATCC 25922 
was made on the Muller Hinton agar. A Cefoxitin disc (30µg) was placed in 
the centre of the plate. With a sterile Surgical blade, a slit (3 cm) beginning 
3mm away from the edge of the disc was cut in the agar in an outward radial 
direction. A small circular well is made, 5mm inside the outer edge of the slit. 
By using a pipette 30µl of enzyme preparation was dispended into the slit, 
avoiding slit overfill. AmpC positive and negative controls were included in 
the study. The plates were incubated overnight at 37º C. 
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 The isolates showing clear distortion of zone of inhibition of Cefoxitin 
 
is taken as AmpC producers. ( Fig - 6 ). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig – 6: AmpC Detection using Modified 3 dimensional  
(M3D) assay 
 
 
 
 
 
 
 
 
Test positive 
 
 
 
 
 
 
 
ATCC – AmpC  
positive Control Test negative 
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 Ceftazidime- Imipenem Antagonism Test
45
: 
 
 
This method is also used for the detection of wild type inducible Amp C 
producers. 
 
A 0.5 Mc Farland of test isolate was taken with the help of a sterile non 
toxic cotton swab and spread over Muller Hinton agar plate. Ceftazidime ( 
30µg) and imipenem ( 10µg) disc were placed 20 mm apart from centre to 
centre.It was incubated at 35 º C for 16 to 20 hrs. 
 
Interpretation; isolates showing blunting of Ceftazidime zone of inhibition 
adjacent to imipenem disc are confirmed as positive for inducible AmpC β 
Lactamase production. ( Fig –7). 
 
 
Fig – 7: AmpC Detection using Ceftazidium –  
imipenem antagonism (CIAT) assay  
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 Boronic acid inhibition based test
44
 ;            
 This test was carried  out for the  detection  of  both  inducible  as 
well as non  inducible AmpC β- Lactamase producing  isolates against 
Cefoxitin ( 30 µg) , Cefotaxime ( 30 µg) and Ceftazidime ( 30 µg)  antibiotic 
discs with and without boronic  acid( 400µg). Preparation of boronic acid 
stock solution; Phenylboronic acid 120 mg was dissolved  in 3ml of 
dimethyl  sulfoxide  ( DMSO) , 3 ml Of sterile distilled water , added 
to  this  solution to get  a final concentration  of  20 mg /ml .now from this 
stock solution  20 µ l were added to each of the  cephalosporin/ boronic 
acid ( 30µ g /400µg.). A  0. 5 Mc Farland of test isolate was spread 
over Muller Hinton  agar plate and inoculums was allowed  to dry for 
5 to 10 min  with lid in place. The above mentioned antibiotic discs- 
Cefoxitin ( 30 µg ) , Cefotaxime ( 30 µg) ,  Ceftazidime  (  30 µg ) with 
and with out boronic acid ( 400 µg) were applied using aseptic 
technique at a distance of 20 mm   from each other The plates were 
incubated in inverted position at 35 
0
 C for  16 to 20 hrs.       
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 Interpretation: A ≥ 5mm increase in zone diameter for either anti 
microbial tested in combination with boronic acid versus its zone when tested 
alone confirms Amp C .β- lactamases production. ( Fig –8). 
 
 
 
 
 
 
 
 
Fig – 8: AmpC Detection using Boronic Acid  
inhibition test (BAIT) assay 
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 Cloxacillin combined disc diffusion test 
46
. 
 
 
This test was used for inducible and non inducible Amp C detection 
using Cefoxitin ( 30 µg ) and Ceftazidime ( 30 µg) antibiotic discs with and 
with out Cloxacillin ( 400 µg) .Antibiotic discs : Cefoxitin ( 30 µg) and 
Ceftazidime ( 30µg). were obtained commercially while 
 
Cefoxitin/ cloxacillin disc was prepared in laboratory by adding 10 µl of 
cloxacillin stock solution to each cephalosporin ( 30 µg) disc. 
 
 
Preparation of cloxacillin stock solution: 
 
 
 
20 mg of cloxacillin powder was dissolved in one ml of sterile distilled 
water to get a final concentration of 20 mg/ ml. the solution was vortexed for 
one min to make it homogenous. Now from this stock solution 10 µl were 
added to each of the cephalosporin / cloxacillin disc ( 30 µg/ 200µg). 
 
 
 
 
A 0.5 M c Farland of test isolate was spread over Muller- Hinton agar 
plate and inoculums was allowed to dry for 5 to 10 min. The above mentioned 
antibiotic disc are applied using aseptic technique at a distance of 20 mm from 
each other.The plates were incubated in inverted position at 37 
0
 C for 16 to 20 
hrs 
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 Interpretation: A ≥ 5mm increase in zone diameter for either 
 
antimicrobial tested in combination with cloxacillin versus its zone 
 
when tested alone confirm Amp C β- Lactamase Production. ( Fig –9) 
 
 
 
 
 
 
 
 
Fig – 9: AmpC Detection using Disc Cloxacillin 
 
combined disc diffusion test assay 
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 Disc antagonism test
47
: For inducible AmpC detection   
 A  0.5 Mc Farland  of  test isolate was taken with the  help  of  a 
sterile cotton   swab and spread over Muller- Hinton agar plate. 
Cefotaxime ( 30 µg ) and Cefoxitin ( 30 µg) disc were placed 20 mm 
apart from  centre  to centre. The plates were incubated  at 37
0
 C for  16 
to 20 hrs .           
 
 
Interpretation; isolates showing blunting of Cefotaxime zone of 
inhibition adjacent to Cefoxitin disc were positive for inducible AmpC β 
Lactamase producers. ( Fig –10) 
 
Fig – 10: AmpC Detection using Disc Antagonism test (DAT) 
assay  
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 Double disc Synergy test
46
 : 
 
 
The Surface of the Muller – Hinton agar plates were inoculated with a 0. 
5 Mc Farland suspension of test isolate. Place one Cefotaxime ( 30 µg ) and 
one Ceftazidime ( 30 µg ) disc on an inoculated MH agar plate.In between 
apply one Boronic Acid disc at a distance of 10 
 
mm (edge to edge ). If the strain was totally resistant to the Cephalosporins 
combination , the distance should be reduced to 5 mm 
 
.Also, apply one Ceftazidime ( 30 µg ) , and one Cefotaxime ( 30 µg) disc, in 
between the two disc at a distance of 5 to 10 mm dge to edge , place one 
Cloxacillin disc . 
 
 
Interpretation: A keyhole or ghost zone ( synergism ) between Boronic 
Acid and any of Cefotaxime or Ceftazidime indicates the presence of an Amp 
C β Lactamase. 
 
 
A keyhole or ghost zone between Cloxacillin and Ceftazidime and or 
Cefotaxime indicates the presence of an Amp C β-Lactamase. ( Fig –11) 
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Fig – 11: AmpC Detection using Double disc synergy 
 
test (DDST) assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DETECTION OF AMPC BY MOLECULAR METHODS: 
 
Multiplex PCR; 
 
 
Multiplex PCR was performed on randomly picked 106 cefoxitin 
resistant  isolates , of which 82 isolates were  confirmed phenotypically  to 
be  positive  for Amp C β- lactamase production and 24 isolates negative by 
modified 3 dimensional (M3D) test .  For   partial  gene PCR amplification, 
 
primers (Table-2) specific for different beta lactamase gene are used for 
reaction with bacterial DNA as template. 
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 Table – 2: Oligonucleotides used as primers for amplification of different 
 
AmpC β- lactamases gene groups ( Perez and Hanson, 2002) 
 
 
TARGET  PRIMER SEQUENCE - 5’ to 3’  Expected 
       amplicon 
       size (bp) 
    
MOX-1,MOX- MOXMF GCTGCTCAAGGAGCACAGGAT 520 
2,CMY-1,  MOXMR CAATTGACATAGGTGTGGTGC  
CMY-8 to       
CMY-11        
     
LAT-1 to LAT- CITMF TGGCCAGAACTGACA GGC 462 
4,CMY-2 to CITMR AAA     
CMY-7,BIL-1  TTTCTCCTG  AACGTG GCT 
   GGC     
      
DHA-1,  DHA- DHAMF AACTTTCACAGG TGT GCT 405 
2  DHAMR GGG T     
   CCGTACGCATACTGG CTT TGC  
      
ACC  ACCMF AACAGCCTCAGCAGC CGG 346 
  ACCMR TTA     
   TTC GCC GCA ATC 
   ATCCCTAGC    
    
MIR-1T, ACT- EBCMF TCGGTAAAGCCGATGTTGCGG 302 
1  EBCMR CTT CCA CTG CGG 
   CTGCCAGTT    
      
FOX-1 to FOXMF AACATGGGGTATCAGGGA  190 
FOX-5b  FOXMR GAT G     
   CCAAGCCCG TAACCGGATTGG  
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 Preparation of DNA template; DNA is extracted by boiling centrifugation 
method ( Freshchi et al . 2005 ). 
 
Preparation of reaction mixture; 
 
 
Each single reaction mixture ( 30 µl) contained 10µl of DNA 
suspension, 15 pmol of each primer ( Sigma) , 10 m M d NTPs, 1 U Taq DNA, 
polymerase, 25 Mm Mg Cl 2, and 2.5 µl of 10 x Taq buffer. 
 
Reaction condition; PCR was performed using thermal cycler (fig – 12) with 
the following running conditions; initial denaturation step at 94’ C for 5 min, 
followed by 39 cycles using following parameters; 
 
DNA denaturation 94’ C for  1 min 
Primer annealing 60’ C for 45 sec 
Primer extension 72’C for 1 min. 
 
 
After the last cycle,  a final extension  step  at 72’C for 7 min  was added. 
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 Visualization of PCR product; 
 
 
 
The DNA fragments of the AmpC genes amplified by PCR are 
identified by agarose gel electrophoresis. 5µl of amplified product from 
 
PCR is electrophoresed on 1.5% agarose gel, at constant 60 volts for 60 min 
with Tris Acetate EDTA ( TAE) buffer. Molecular marker of 100 bp DNA 
ladder, is run concurrently. The gel stained with ethidium bromide is visualized 
under ultraviolet illumination and saving of image for the presence of bands 
using Multi –image Light Cabinet, is done. ( Fig – 13a & 13b). 
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Fig – 12: PCR thermocycler  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig – 13a: Gel electrophoresis set up 
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Fig – 13b: Gel picture of Genotypic detection of AmpC 
 
betalactamases 
 
 
 
 
 
 
 
 
 1000 bp   
    
  
500 bp 
 
 
MOX 
     
      
     CIT 
    
  
100 bp 
 
 
FOX      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and Analysis 
 
 RESULTS AND ANALYSIS 
 
 
Out of the 256 isolates of Enterobacteriaceae included in the study , 
most isolates were from urine specimen 30% ( 78) followed by blood 16% (40) 
and others as seen in Fig - 14 
 
 
 
 
 
Fig – 14: Specimenwise distribution of Enterobacteriaceae 
 
included in the study  
 
 
 
 
 
 Tissues  Urine  Blood  Sputum  Bal  Tracheal asp  Pus  Bodyfluids 
 
12% 
9% 
 
 
14% 
 
30% 
 
5% 
 
5% 
 
9%  
16% 
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 Fig – 15: Distribution of various Microorganisms ( n-256) 
 
included in the study  
 
 
 
 
 
 
 
 Klebsiella pneumoniae 
 
 
 
 
 
 
 
 E coli 
 
 
 
 
 
 
 
 Citrobacter spp 
 
 Enterobacter sp 
 
 Proteus sp 
 
 Serratia marscesens 
 
 
 
8% 
 
8% 
28% 
 
 
13% 
 
 
 
11% 
 
32% 
 
 
 
 
 
 
 
 
 
 
 
 
Of the 256 cefoxitin resistant isolates included in the study E coli 32% (85) and 
Klebsiella pneumoniae 28.9% (74) were the predominant isolates followed by 
the others . (Fig – 15) & (Table –3) 
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 TABLE- 3: Showing distribution of clinical isolates screened positive for 
 
Amp C beta lactamases by Cefoxitin screening test 
 
 
 
 
ORGANISMS 
CEFOXITIN 
RESISTANCE ( %)  
  
Klebsiella pneumoniae 74 (28.9) 
  
E.coli 85 (32.2) 
  
Citrobacter spp 30 (11.7) 
  
Enterobacter spp 34 (13.2) 
  
Proteus spp 21(8.2) 
  
Serratia spp 12 (4.6) 
  
TOTAL 256 (100) 
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 Table – 4: Detection of AmpC betalactamases by various phenotypic 
 
methods 
 
 
Organisms DAT CIAT BAIT CCDD DST M3D 
       
Klebsiella 56 62 64 15 59 63 
(n=74) (77%) (86%) (86.3%) (20%) ( 81%) (87.5%) 
       
Ecoli 40 43 56 30 30 64 
( n= 85) (47%) (50%) (65.8%) (35%) (35%) (75.2%) 
       
Enterobacter 15 18 24 16 15 20 
aerogenes (41%) (50%) (66%) (44.4%) (41.6%) (55.5%) 
( n= 34 )       
       
Citrobacter 18 19 17 5 3 19 
Spp (60%) (63%) (56.6%) (16.6%) (10%) (63.3%) 
( n=30 )       
       
Proteus spp 9 12 10 5 4 (19%) 11 
(n=21 ) (42.8%) (57%) (47.6%) (23%}  (52%) 
       
Serratia 2 3 5 1 3 5 
marcescense (15.3%) (25%) (41%) (8.3%) (25% ) (41%) 
( n=12)       
       
TOTAL (256) 140 157 176 72 114 182 
 (54.6%) (61.3%) (68.75) (28.1%) (44.53%) (71.09) 
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 Out of the 256 cefoxitin resistant enterobacteriaceae isolates 182 
(71.09%) of the isolates were found to be AmpC producers by the gold 
standard Modified 3 D (M3D) assay . Boronic acid inhibition test (BAIT) 
detected 176 (68.75%) isolates as AmpC producers followed by Ceftazidime – 
Imipenem Antagonism test (CIAT) ,Disc Antagonism Test (DAT ) , Double 
disc synergy test (DST) & Cloxacillin Combined Disc Diffusion test (CCDT) 
as seen in the table – 4. 
 
TABLE – 5: Sensitivity and Specificity of various AmpC phenotypic 
 
detection methods 
 
 
 
Disc Ceftazidime- Boronic 
Cloxacillin 
Double  
combined  
antagonism imepenem acid disc  
disc  
test antagonism inhibition synergy  
diffusion   
test test test   
test      
      
Sensitivity 
86.72% 87% 93.96% 87.5% 86.72%  
      
Specificity 
66.4% 78% 93.24% 79% 66.6%  
      
Accuracy 
75% 83.5% 93.75% 84.37% 72%  
      
 
 
 
 
Among the various phenotypic methods tested for AmpC producers, 
BAIT had the highest sensitivity (93.96%) and specificity (93.24%) followed 
by CIAT and CCDT with similar sensitivity and specificity .DAT and DST had 
the least sensitivity (86%) and specificity (66%) (Table – 5) 
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 Table – 6:Distribution of Enterobacteriacae isolates subjected to molecular 
 
detection of AmpC genes 
 
 
 M3 D M3D 
TOTAL 
Organisms POSITIVE NEGATIVE  
Klebsiella pneumoniae 34 5 
39 
 
    
E coli 27 5 32 
    
Citrobacter sp 7 4 11 
    
Enterobacter sp 10 6 16 
    
Proteus sp 4 2 6 
    
Serratia sp 0 2 2 
    
Total 82 24 106 
    
 
 
 
 
About 106 randomly selected cefoxitin resistant enterobacteriaceae 
isolates with 82 positive for AmpC by M3D assay and 24 negative for M3D 
assay were further subjected to Molecular detection of te well identified 6 
AmpC betalactamases gene groups (Table-6). 
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 Table 7 : Positive for Amp C Betalactamase genes among strains positive 
 
and negative by M3D assay 
 
 
 M3D (+ VE) M3D ( - VE) 
Organisms     
 
No of 
AmpC 
No of 
AmpC 
 
genes (+ genes  
isolates isolates  
VE) (+ VE)    
     
Klebsiella 
34 30 5 2  ( FOX) 
pneumonia     
     
E coli 27 21 5 0 
     
Citrobacter sp 10 5 6 0 
     
Enterobacter sp 7 3 4 0 
     
Proteus sp 4 2 2 0 
     
Serratia sp 0 0 2 0 
     
TOTAL 82 61(74.3%) 24 2 (8.3%) 
     
 
 
 
 
About 61 (74.3%) of the M3D assay positive isolates and 2 (8.3%) of the 
M3D assay negative isolates were found to harbor Amp C genes ( Table –7) 
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 TABLE -8 : Different AmpC Betalactamases gene groups among isolates 
 
that were M3D assay positive 
 
 
M3D + ve FO MO DH CI EB AC CIT FOX+ FOX+ TO 
Organisms X X A T C C MO MOX+ MOX+ TA 
       X CIT CIT+A L 
         CC  
           
Klebsiella 8 5 2 2 0 0 5 4 4 30 
           
E coli 5 3 2 2 0 1 2 3 3 21 
           
Citrobacter 2 1 0 0 0 0 2 0 0 5 
           
Enterobact 1 0 0 0 0 0 0 0 2 3 
er sp           
           
Proteus sp 1 0 0 0 0 1 0 0 0 2 
           
Serratia sp 0 0 0 0 0 0 0 0 0 0 
           
Total 17 9 4 4 0 2 9 7 9 61 
           
 
 
 
 
Of the 63 isolates positive for AmpC genes, Fox (55.5%) was the commonest 
gene group identified which were also found in 2 (8.3%) M3D assay negative, 
followed by MOX (53.9%) , CIT(46%) and others . More than one genes were 
present in 26(41.2%) of the isolates (Table-7 & 8) 
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Fig – 16 : Antibiotic sensitivity pattern of the AmpC betalactamase 
 
 producing isolates 
   
 Sensitivity (%) 
NF 
  
42.96  
NF 49.6  
NA 50.7  
OF 47.2  
CL 93.1 
TGC 83.9  
LE 56.6  
TB 52.3  
NT 56.6  
CFS 48.04  
CO 44.5  
PT 50.78  
MR 75.7  
DO 42.96  
CF 42.18  
AMIKA 74.6  
GENTA 48.04  
   
    
 
 
The Antibiotic susceptibility pattern of the AmpC producing 
enterobacteriaceae showed colistin to be the most sensitive (93.1%) followed 
by Tigecycline (83.9%), Meropenem ( 75.7%) , Amikacin (74.6%) and others ( 
Fig -16) 
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 Ceftazidime and ceftazidime clavulunic acid helped in the phenotypic 
detection of ESBLs production among the AmpC producers .(54% ) . along 
with those that were resistant to carbapenems (24%). Fig -17. 
 
 
 
 
 
 
 
 
 
Fig -17: AmpC producing isolates occurring with ESBLs and Carbapenem 
 
ressistance  
 
 
 
 AmpC  ESBLs and AmpC  ESBLs AmpC & Carbapenem resistant 
 
 
 
 
 
24% 22% 
 
 
 
 
 
 
 
 
 
54% 
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Discussion 
 
 DISCUSSION 
 
 
 
 
Despite the discovery of Amp C  lactamases at least 3 decade ago 
Confusion still exists about the importance of their resistance mechanisms, 
optimal test methods and appropriate reporting protocols.
1
 Increasing 
prevalence may be due to exposure to previous empirical cephalosporin therapy 
which is a known selective pressure for increasing AmpC production among 
them.
2
Failure to detect these enzymes has contributed to their uncontrolled 
spread and sometimes to therapeutic failures.
1 
 
 
 
Although there are no CLSI guidelines for phenotypic methods to 
screen and detect AmpC activity in Enterobacteriaceae, several methods have 
been developed for the detection of AmpC, namely, the modified three-
dimensional test,
44
 inhibitor based methods employing Boronic acid,
44
 and 
others . Reduced susceptibility to Cefoxitin is one of the screening methods for 
putative AmpC enzyme detection.
42
 ACC types seem to be the only known 
enzymes that can be missed by cefoxitin screening.
42 
 
 
 
In the present study, out of the 256 Cefoxitin-resistant 
enterobacteriaceae isolates, only 182 (71.9%) were found to be positive for 
AmpC production by the Modified three dimensional assay. Amp C negative 
Cefoxitin resistance may be attributed to ESBLs and MBL production or non- 
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 enzymatic mechanism such as porin channel mutation.
48
 Overexpression of 
chromosomal AmpC gene due to mutation in the promoter or attenuator 
regions.
48
 The other reason is that Cefoxitin has been demonstrated as a 
substrate to active efflux pump in clinical isolates.
48 
 
 
 
The  microorganism  that  were  predominantly  AmpC  producers  were 
 
Klebsiella pneumonia, E coli, , followed by Citrobacter sp , Enterobacter sp , 
 
Proteus  sp  Serratia  marscence.  These  findings  were  consistent  with  most 
researchers .42, 44,45,46,47 
 
 
 
 
 
Among the five phenotypic methods tested against modified three 
dimensional assay , the boronic acid inhibition test had the highest sensitivity 
(93.96%) and specificity (93.24%) compared to the others (Table-5). The use 
of phenylboronic acid in combination with cefoxitin as a phenotypic screening 
method may be a better tool for laboratory diagnosis and confirmation of 
AmpC producing Enterobacteriaceae.
47 
 
 
 
However, Both the modified three dimensional test, and boronic acid 
test fail to distinguish between plasmid-mediated AmpC production and 
derepressed hyperproduction of chromosomal AmpC.
49
 Detection of AmpC 
beta lactamases in Klebsiella sp, Citrobacter koseri, or Proteus mirabilis is 
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 confirmatory for plasmid mediated AmpC production because these organisms 
lack chromosomal AmpC betalactamses .
42 
 
 
 
Inspite of many phenotypic tests, PCR is considered the gold standard 
which is not available for routine diagnostic laboratories. In this study, among 
the 106 isolates tested , 61 Amp-C genes groups were detected among 74.3% 
of the positive phenotypic isolates and 2.8% of the negative isolates. 
 
 
 
Discrepancy between genotypic and phenotypic tests may be due to the 
following reasons: The presence of more AmpC beta-lactamases genes that 
continue to expand beyond those contained in the six families of genes covered 
by PCR.
46
 The other explanation is that the isolates were most likely to be 
hyper-producers due to over-expression of chromosomal AmpC gene.
46
 False 
negative results may be explained by the fact that the genes are detected by 
PCR but not effectively expressed phenotypically.
46 
 
 
 
FOX group genes (including FOX-1) were the predominant type in all 
isolates (55.5%) followed closely by MOX group gene ( including CMY-1) 
(53.9%) then CIT group genes (including CMY-2) (46%) compared to the 
result of Fam et al.
50
, who reported that, in clinical isolates of 
Enterobacteriaceae from Cairo, Egypt Amp-C genes were detected in 28.3% of 
the study population including E. coli, Klebsiella and P. mirabilis. CMY-2 
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 enzyme was found disseminating in all 6 AmpC-positive E. coli and in 6/10 of 
Klebsiella species. Only one K. pneumoniae isolate harbored CMY-4 while 
DHA-1 was detected in 3 Klebsiella and in one P. mirabilis isolate. On the 
other hand the result of Montgomery et al.
51
who reported that 22 AmpC genes 
were detected in 25.8% of the positive cefoxitin screened isolates of which 
40.9% belonged to each of the MOX and the FOX families, 13.6% belonged to 
the EBC family, and 4.5% belonged to the CIT family. 
 
 
 
In a study by Soha A El Hady ,
51
 both CMY-1 and CMY-2 were the 
most common genes detected in their region at Egypt ,DHA-type enzymes 
have been previously identified in Taiwan 
53
 and in China 
54
. In Korea DHA-, 
CMY/MOX-, and ACT-1/MIR-1-type enzymes have also been identified 
55
.While in the United States, in addition to the types mentioned above, DHA-, 
ACT-1/MIR-1, and FOX-type enzymes have been identified 
56
. 
 
 
 
In Japan, MOX-1, CMY-9,CMY-19, CFE-1, CMY-2 and DHA-1 have 
been found in clinical isolates 
57.
 Enzyme type CMY-2 is widely distributed 
geographically. It has been reported in Algeria, France Germany, Greece, India, 
Pakistan, Taiwan, Turkey, United Kingdom and the United States. Several 
studies for the detection of AmpC b-lactamase producers in many countries 
(Saudi Arabia, Taiwan, Korea, North and South America) revealed 
geographical discrepancy in AmpC b-lactamase types 
58 
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 In our study, in 41.26% of the isolates, there were more than one gene. 
Nine isolates K. pneumoniae, nine isolates had both MOX (CMY-1) & and 
CIT(C isolates had three genes CMY-1, CMY-2 and FOX-1 and Nine more 
had CMY-1, CMY-2 , FOX-1 and ACC . For E. coli 6 isolates have both 
CMY-1 and CMY-2, 3 isolates have CMY-1, FOX-1 and 2 isolates have the 
three genes CMY-1, CMY-2 and FOX-1. Similar findings were reported by 
Soha A El Hady et al and Wassef et al 
46
. These Plasmid-mediated AmpC β-
lactamases pose a big challenge to infection control due to the fact that the 
AmpC gene can be expressed in larger amounts and has high transmissibility to 
other bacterial species. 
46 
 
 
 
Enterobacteriaceae-producing both AmpC and ESBL have been 
increasing reported worldwide. As per CLSI guidelines 
42
,when using the new 
interpretive criteria, routine ESBL testing is no longer necessary before 
reporting results (i.e. it is no longer necessary to edit results for cephalosporins, 
aztreonam, or penicillins to resistant). 
59
 However, ESBL testing may still be 
useful for epidemiological or infection control purposes. 
 
 
 
In this study, co-production was observed in 54% of isolates. This is 
comparatively higher than that reported by Devaraju
60
 (24%) and Nasir et al.
61
 
(11.5%). ESBLs detection tests may be insufficient in situations where high-
level expression of AmpC may mask recognition of ESBL. Cefepime is a more 
reliable detector in the presence of AmpC as it is stable to the enzyme and will 
69 
 thus demonstrate synergy arising from inhibition of ESBL by Clavulanate in 
the presence of AmpC
62
 Some studies suggest the use of Cefepime-
Clavulanate Etest as a suitable substitute.
62 
 
 
 
Carbapenems the drugs of choice for treating ESBLs and Amp C 
producing bacteria was found to have 75% sensitivity only . Colistin had the 
highest sensitivity followed by Tigecycline and Amikacin. Colistin is never 
administered as a monotherapy and caution exercised with increasing 
tigecycline and Colistin intrinsically resistant isolates such as Proteus sp which 
are Amp C producers 
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Summary 
 
 SUMMARY 
 
 
 
 
With the increasing use of β-lactam drugs and introduction of various 
inhibitor combinations AmpC β-lactamases have emerged and are being 
reported globally among enterobacteriaceae with varying prevalence rates. 
 
 
 Though AmpCs are associated with serious life threatening illness, 
detection of Amp C β-lactamases are very difficult and not routinely 
tested .



 This study aimed at comparing various phenotypic methods and also 
look for various AmpC gene clusters using multiplex PCR.



 About 256 non repeat Enterobacteriaceae clinical isolates that were 
cefoxitin resistant were included in the study conducted during the 
period Jan 2016 – July 2017.



 Urinary isolates were the predominant , followed by blood isolates and 
others
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  E coli 32%(85)was the predominant isolate followed by Klebsiella 
pneumonia 28.9%(74), Enterobacter sp , Citrobacter sp , Proteus sp and 
Serratia marscesens.



 All the isolates were subjected to phenotypic detection of AmpC by 6 
methods such as Modified three dimensional (M3D) assay , Boronic 
acid Inhibition test ( BAIT), Ceftadidime – imipenem antagonism test 
(CIAT), Disc Antagonism test ( DAT), Double disc synergy test (DST) 
and Cloxacillin Combined disc diffusion test (CCDT)
 
 
 
 About 182 (71.09%) of 
AmpC.Cefoxitin resistant
 
 
 
the isolates were found to produce AmpC 
betalactamase negative maybe 
 
attributed to porin mutations, over expression of chromosomal 
 
AmpC.and active efflux mechanism . 
 
 
 
 
 
 Amp C was found to be produced highest among Klebsiella 
 
pneumoniae (87.5%) followed by E coli (75.2%) and others 
 
 
 
 
 
 BAIT test had the highest sensitivity (93.96%) and specificity (93.24%) 
comparable to M3D assay.
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  About 106 randomly selected Cefoxitin resistant Enterobacteriaceae 
with 82 positive for AmpC by M3D assay and 24 negative for M3D 
assay were subjected to multiplex PCR for 6 AmpC gene clusters such 
as MOX, CMY-2, DHA, ACC, MIR/ACT, FOX.



 Sixty three of the 106 isolates were found to harbor one / more Fox
 
(55.5%) was the commonest gene group identified  , followed by MOX 
 
(53.9%) , CIT(46%) and others . 
 
 
 
 
 Two M3D negative isolates were tested positive for FOX.
 
 
 
 
 
 More than one genes were present in 26(41.2%) of the isolates . Nine 
isolates were found to have the genes FOX,MOX, CIT, ACC. 
 
 
 
 Antibiotic  sensitivity  testing by routine Kirby bauer’s disc diffusion
 
showed colistin to have the highest sensitivity (93%) followed by 
Tigecycline 83.9%, Meropenem 75.7% Amikacin 74.6%. 
 
 
 
 AmpC coexisting with ESBLs was found among 54% of the isolates 
tested and 24% isolates also was found to be carbapenem resistant.
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  Identifying the types of AmpC aid in hospital infection control and help 
physicians to prescribe the most appropriate antibiotic.



 Continual surveillance of AmpC resistance mechanisms that assist 
appropriate antibiotic therapy and better patient outcomes and also 
reduces antibiotic resistance through better infection control practices.



 Sequencing and typing the strains may be required to better understand 
the genetic relatedness and the molecular epidemiology of their 
resistance mechanism
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Conclusion 
 
 CONCLUSION 
 
 
 
 
Clinical laboratories needs to be upgraded with appropriate tools and 
qualified staff to recognize newer drug resistances emerging among 
Enterobacteriaceae. Amp C betalactamases producing bacteria are being 
frequently isolated from clinical samples and these enterobacteriaceae isolates 
also harbouring ESBLs and Carbapenemases is a concern, as they increase the 
complexity of their detection . Boronic acid inhibitor method using Cefoxitin 
reliably detected AmpC phenotypically. The most prevalent AmpC genes 
belonged to FOX, MOX and CIT in our study . The dissemination of these 
plasmid-mediated resistance genes within the hospital is an important public 
health issue. Identifying the types of AmpC may aid in hospital infection 
control and help the physician to prescribe the most appropriate antibiotic, thus 
decreasing the selective pressure, which generates antibiotic resistance. 
Sequencing and typing the strains may be required to better understand the 
genetic relatedness and the molecular epidemiology of their resistance 
mechanism. The study emphasizes the necessity for continual surveillance of 
resistance mechanisms that assist appropriate antibiotic therapy and better 
patient outcomes and also reduces antibiotic resistance through better infection 
control practices. 
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Appendix 
 
 
 
 
 
 
  ABBREVIATIONS 
AmpC - Betalactamase enzyme. 
BAIT - Boronic acid inhibition test. 
CIAT - Ceftazidime-Imepenem  inhibition test. 
CCDT - Cloxacillin Combined  disc diffusion test. 
DAT - Disc antagonism test. 
DST - Double Disc synergy test. 
M3DT - Modified 3 dimension  test. 
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